Literature DB >> 22926344

Clinical trials: Phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis.

Emma Leah.   

Abstract

Entities:  

Year:  2012        PMID： 22926344     DOI： 10.1038/nrrheum.2012.145

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  2 in total

1.  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

Authors:  Roy Fleischmann; Joel Kremer; John Cush; Hendrik Schulze-Koops; Carol A Connell; John D Bradley; David Gruben; Gene V Wallenstein; Samuel H Zwillich; Keith S Kanik
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245

2.  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

Authors:  Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson
Journal:  N Engl J Med       Date:  2012-08-09       Impact factor: 91.245
  2 in total
  4 in total

Review 1.  Tofacitinab in renal transplantation.

Authors:  Martin S Zand
Journal:  Transplant Rev (Orlando)       Date:  2013-07       Impact factor: 3.943

2.  The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.

Authors:  Maurizio Cutolo
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-02       Impact factor: 5.346

Review 3.  Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis.

Authors:  Maurizio Cutolo; Marianna Meroni
Journal:  J Inflamm Res       Date:  2013-11-15

Review 4.  JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.

Authors:  Karoline Gäbler; Iris Behrmann; Claude Haan
Journal:  JAKSTAT       Date:  2013-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.